



Company Announcement

Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. Patent for the Neoantigen Selection Method for VB10.NEO, Nykode's Individualized Neoantigen Therapy

Oslo, Norway, November 4, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,462,898, entitled, "Method For Selecting Neoepitopes".

Nykode is positioning VB10.NEO as a leading individualized neoantigen therapy, building on experience with an established manufacturing supply chain and a proprietary neoantigen target selection algorithm proven to drive immune responses in two clinical trials.

The newly issued patent relates to Nykode's proprietary NeoSELECT™ platform which is used for the selection of neoantigens for the company's fully individualized neoantigen-based therapy, VB10.NEO. The 20-year expiration date of this patent is September 27, 2039. Related patents were previously granted to the company in Australia, China, Israel, Japan and Russia.

The new U.S. patent complements last year's U.S. patent describing the company's individualized neoantigen therapy VB10.NEO.

Michael Engsig, CEO of Nykode, said, "This patent underscores Nykode's continued innovation and leadership in the field of individualized cancer immunotherapy. Expanding our IP portfolio remains a cornerstone of our strategy to strengthen our leading position and further advance truly individualized cancer treatments for patients."

About VB10.NEO

VB10.NEO is a proprietary individualized neoantigen therapy in development for the treatment of locally advanced or metastatic solid tumors. The product is designed to be produced on-demand based on each patient's unique neoantigen profile, identified through Nykode's AI-powered NeoSELECT™ platform, which integrates individual patient multiomics data to select the most immunogenic neoantigens. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system.



Nykode has evaluated VB10.NEO in two Phase 1 clinical trials, VB N-01 and VB N-02. VB N-01 was a first-in-human study in patients with advanced solid tumors, designed to assess safety, feasibility, and immunogenicity of VB10.NEO in combination with standard-of-care treatment, including checkpoint inhibitors. VB N-02 was a Phase 1b study conducted in heavily pre-treated patients with advanced solid tumors (median 5 prior lines of treatment), aiming to further optimize dose and regimen in combination with the checkpoint inhibitor atezolizumab (Tecentriq®).

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA
IR@nykode.com



Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway